Collaborations

Agreements inked to develop novel molecular imaging agents

Published in Cancer Weekly, March 30th, 2004

Bristol-Myers Squibb Medical Imaging, Inc., and Kereos, Inc., announced that the companies have entered into agreements for the development and commercialization of novel molecular imaging agents.

Designed to detect disease on a molecular level, these agents could potentially enable earlier, more effective diagnosis and highly targeted treatment of cardiovascular diseases and cancer.

Under the terms of the agreements, the companies will work together to develop molecular imaging agents for cardiovascular diseases and cancer using Kereos' core technology. Bristol-Myers Squibb Medical Imaging has obtained exclusive worldwide rights to develop and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry